Navigation Links
Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
Date:1/25/2012

COLUMBIA, Md., Jan. 25, 2012 /PRNewswire/ -- The Maryland Stem Cell Research Commission (Commission) has announced a new program for pre-clinical and clinical research grants. This program will support for-profit companies in advancing medical therapies using human stem cells. The Commission has issued a new request for Applications (RFA), RFA-MD-12-4, soliciting proposals for this program.

"In Maryland, we stand on the cutting edge of technology and innovation," said Governor O'Malley. "To grow Maryland's biotech and life sciences assets, this session, we are proposing $10.4 million to continue the State's investment in Stem Cell Research. I am pleased that the Maryland Stem Cell Research Commission will help our State continue to create jobs and tap into science and discovery. Together, with business and government partners alike, we can continue to make critical investments in the way we feed, fuel and heal our world."

Established under the Maryland Stem Cell Research Act of 2006, the Maryland Stem Cell Research Fund (MSCRF) supports all types of human stem cell research in the State of Maryland. In response to the three RFAs previously issued for the current funding cycle, the Commission has received 179 research applications: 30 Investigator-Initiated, 105 Exploratory and 44 Post-Doctoral Fellowships proposals, maintaining a continued high level of interest from the scientific community. The new RFA was created to accelerate the pace of stem cell research in Maryland and to continue to return the State's investment by stimulating the local economy.

"Moving research as rapidly as possible from the laboratory to pre-clinical and clinical trials will shorten the time patients must wait to benefit from emerging new stem cell therapies," said Margaret Conn Himelfarb, MPH, Chair of the Commission. "Our new RFA is intended to strategically and responsibly expedite this critical stage of scientific development. It marks a major milestone toward realizing the goal of the Maryland Stem Cell Research Act, and helps support the State's burgeoning biotech industry."

Because its proximity to U.S. Food and Drug Administration (FDA) makes Maryland an attractive location for life sciences companies, the Commission hopes this program will help attract new companies to the State. Maryland-based companies of all types are eligible to apply for RFA-MD-12-4. Companies conducting clinical research may be based elsewhere in the United States, but the work funded under this RFA must be conducted at a site in Maryland. Companies conducting pre-clinical research must be based in Maryland. No MSCRF funding will be used to support work conducted outside of Maryland.

Applicants for pre-clinical research grants may request up to $500,000 in direct costs, and applicants for clinical research grants are eligible to receive up to $750,000 in direct costs. Both grants will be budgeted over a period of up to three years. RFA-MD-12-4 is intended only for companies requesting funds for projects that have achievable milestones. Studies must comply with all FDA guidelines. In pre-clinical applications, preference will be given to late-stage pre-clinical research. Proposals that involve a clinical trial must have an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) cleared by the FDA for the therapy or device under investigation, before the application is submitted to MSCRF for review.

Pre-clinical research grant awards require a 1:2 match (applicant:MSCRF), all or part of which may be an in-kind match. Clinical research grant awards require a 1:1 match (applicant:MSCRF), all or part of which may be an in-kind match. In-kind matches may include personnel, salaries and equipment.

Applicants are required to electronically submit a pre-application through the Maryland Technology Development Corporation (TEDCO) designated system by going to http://submissions.marylandtedco.org/preapp. The deadline for pre-applications is April 17, 2012, for funding in FY 2013.

For more information about the MSCRF and to view the FY 2011 annual report, please visit www.mscrf.org.

About the Maryland Stem Cell Research Commission
The Maryland Stem Cell Research Fund (MSCRF) was established by the State of Maryland under the Maryland Stem Cell Research Act of 2006 to promote State-funded stem cell research and cures through grants and loans to public and private entities in the State. Administered by the Maryland Technology Development Corporation (TEDCO), the MSCRF is overseen by an independent Commission that sets policy and develops criteria, standards and requirements for applications to the Fund. For more information about the MSCRF and a list of Commission members, please visit www.mscrf.org.

 


'/>"/>
SOURCE Maryland Stem Cell Research Fund
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Stem Cell Research Commission Issues 2012 Requests for Applications (RFAs)
2. Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards
3. Maryland Stem Cell Research Commission Funds 36 New Projects in FY 2011
4. Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland
5. Mtech Announces Winners of the 2011 University of Maryland $75K Business Plan Competition
6. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
7. The University of Maryland Baltimore (UMB) and Paragon Bioservices, Inc. Announce the Formation of a Public-Private Stem Cell Technology Consortium
8. Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition
9. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
10. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
11. Biophysical Society to Hold 55th Annual Meeting in Baltimore, Maryland, March 5-9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Husson ... clinical research community’s growing body of knowledge during its Eighth Annual Research ... and the adjacent Darling Atrium. During the event, undergraduates, graduate students, and faculty ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... technology applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been ... is the global industry association connecting the electronics manufacturing supply chain. The mission ...
(Date:4/20/2017)... , April 20, 2017 Dutch philosopher Koert van Mensvoort ... Nature, at the University of Technology in Eindhoven - has written a ... letter, he calls on humanity to avoid becoming a slave and victim to ... ... Dutch philosopher Koert van Mensvoort – founder of the Next ...
(Date:4/19/2017)... ... 18, 2017 , ... The Vibrating Orifice Aerosol Generator (VOAG) ... monodisperse droplets of known diameters for research applications such as for calibrating droplet ... drying monodisperse droplets. , The VOAG requires forcing liquid out of an ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):